$WINT News

Last published 10mo ago

10mo agoWINTWindtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug CandidatesGlobeNewswireSeismic Pharmaceutical Holdings, LLC acquires the cardiovascular assets and will pay Windtree 20% of any milestone payments, royalty payments or similar economic interests (including all global commercial net revenues)
11mo agoWINTWindtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech SpaceGlobeNewswireWindtree is executing its corporate strategy to diversify its business with revenue and profit generating divisions CommLoan, Inc. is a tech company focused on transforming the way middle market loans are originated
11mo agoWINTWindtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the LicenseeGlobeNewswireThe Company has a global license agreement for the acute pulmonary that could pay up to $78.9 million in development, regulatory and commercial milestones plus low double digit royalties The licensed treatments
12mo agoWINTWindtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent EstateGlobeNewswireWindtree has a total of 59 issued or allowed patents and 17 pending patents for Istaroxime and its SERCA2a activators Windtree received recent notification of allowed Istaroxime patents for acute heart failure in Canada
1y agoWINTWindtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder MeetingGlobeNewswireThe Special Stockholder Meeting on August 28, 2025 recorded the proxy voting approvals of all ten of the Windtree proposals by stockholders The stockholder approved proposals provide the foundation for Windtree revenue
1y agoWINTWindtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025GlobeNewswirePresentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock SCAI Stage C Cardiogenic shock SCAI Stage C has an in hospital mortality rate of 20-30% Istaroxime interim
1y agoWINTWindtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock PatientsGlobeNewswireIstaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses in previous trials
1y agoWINTWindtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and RedemptionGlobeNewswireInvestors choose to redeem or convert the majority of Series C and Series D Preferred 99% of outstanding preferred series C shares are redeemed or converted and preferred series D reduced 68.5% in outstanding shares
1y agoWINTWindtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury StrategyGlobeNewswireUp to $700 Million Committed to BNB Acquisitions, Reinforcing Innovative Crypto Treasury Strategy Ninety Nine Percent of the proceeds from both issuances to be used to buy BNB WARRINGTON, Pa., July 24, 2025 (GLOBE
1y agoWINTKraken and Windtree Therapeutics Announce Strategic Partnership for BNB Custody, Trading, and OTC ServicesGlobeNewswireWARRINGTON, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT) is pleased to announce a strategic partnership with Kraken, a leading global cryptocurrency
1y agoWINTWindtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On SubscriptionsGlobeNewswireWARRINGTON, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT) is excited to announce it has entered into a $60 million securities purchase agreement led
1y agoWINTWindtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart FailureGlobeNewswire1.3 million patients are hospitalized annually in the U.S. from acute heart failure and it is the #1 cause of hospitalization in patients >65 years old If istaroxime is approved in the US for acute heart failure,
1y agoWINTWindtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim AnalysisGlobeNewswireThe SEISMiC C Study is the third study in the istaroxime cardiogenic shock development program - SEISMiC C is studying more severely ill SCAI Stage C cardiogenic shock patients Windtree has previously reported two
1y agoWINTWindtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive GelGlobeNewswireWindtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of 2026 Tech transfer
1y agoWINTWindtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B StudyGlobeNewswireThe Phase 2 Istaroxime study was successful in multiple endpoints showing promise for how it may be utilized if approved in its targeted indications Primary endpoint of the study was met of increasing systolic
1y agoWINTWindtree Receives Offer for Its Preclinical Oncology Drug CandidateGlobeNewswireCompany to receive $7.0 million up front for its preclinical oncology drug candidate Up to $130.0 million in milestone payments starting with initiation of Phase 1 High single digit royalties that could total up to
1y agoADTX WINTEvofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of DirectorsBusiness WireAditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc.
1y agoWINTWindtree Announces Plan for Cryptocurrency Treasury PolicyGlobeNewswireWARRINGTON, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing
1y agoWINTWindtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025GlobeNewswireIstaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime cardiogenic shock
1y agoWINTWindtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure ConferenceGlobeNewswireWARRINGTON, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early
1y agoWINTWindtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business UpdatesGlobeNewswireWARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early
1y agoWINTWindtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025GlobeNewswireWARRINGTON, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early
1y agoWINTWindtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for USGlobeNewswireWARRINGTON, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early
1y agoWINTWindtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline DevelopmentGlobeNewswireWARRINGTON, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early
1y agoEVFM WINTWindtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business UpdatesGlobeNewswireWARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for
1y agoWINTEvofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree TherapeuticsPR NewswireEvofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced that it has entered into a License and Supply Agreement (L&S...
1y agoADTX WINTEvofem Reports Fourth Consecutive Year of Net Sales GrowthPR NewswireWomen's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended December 31, ...
1y agoWINTWindtree Therapeutics Regains Compliance with Nasdaq Listing RulesGlobeNewswireWARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing
1y agoEVFM WINTWindtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved ProductGlobeNewswireWARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing
1y agoWINTWindtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart FailureGlobeNewswireWARRINGTON, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for
1y agoWINTWindtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for IndiaGlobeNewswireWARRINGTON, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for
1y agoWINTWindtree Therapeutics, Inc. Announces Reverse Stock SplitGlobeNewswireWARRINGTON, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology company focused on advancing early and late-stage innovative therapies for
1y agoWINTWindtree Announces Special Late-Breaking Clinical Science Abstract Presentation on Istaroxime at the Technology and Heart Failure Therapeutics ConferenceGlobeNewswireWARRINGTON, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for
1y agoWINTWindtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology PipelineGlobeNewswireWARRINGTON, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for
1y agoWINTWindtree Announces the Addition of Leanne Kelly to Its Board of DirectorsGlobeNewswireWARRINGTON, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for
1y agoWINTWindtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology PipelineGlobeNewswireWARRINGTON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for
1y agoWINTWindtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials ConferenceGlobeNewswireWARRINGTON, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for
1y agoWINTWindtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial ArrhythmiaGlobeNewswireWARRINGTON, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for
1y agoWINTWindtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic TransactionGlobeNewswireWARRINGTON, Pa., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for
1y agoWINTWindtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business UpdatesGlobeNewswireWARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for
1y agoWINTWindtree Announces Leadership Transition Plan With Industry VeteransGlobeNewswireWARRINGTON, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for
2y agoWINTWindtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong KongGlobeNewswireWARRINGTON, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for
2y agoWINTWindtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3GlobeNewswireAfter successful SEISMiC A and B studies in Early Cardiogenic Shock, SEISMiC C will treat more severe SCAI Stage C cardiogenic shock to complete the assessment of the intended Phase 3 patient population Windtree plans
2y agoWINTWindtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the WorldGlobeNewswireWARRINGTON, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for
2y agoWINTWindtree To Present at the ThinkEquity Conference on October 30thGlobeNewswireWARRINGTON, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for
2y agoWINTWindtree Announces Expansion of Patents with Issuance of Istaroxime Patent for JapanGlobeNewswireWARRINGTON, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for
2y agoWINTWindtree Announces Publication of Positive Istaroxime Phase 2b Study Trial DesignGlobeNewswireWARRINGTON, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for
2y agoWINTWindtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic ShockGlobeNewswireIstaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias NYHA heart failure classification was
2y agoWINTWindtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ETGlobeNewswireNew Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert Review of cardiogenic shock and other programs, including Windtree's strategy and planned near-term milestones WARRINGTON,
2y agoWINTWindtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic ShockGlobeNewswireIstaroxime significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many secondary endpoint assessments Study results to be presented at the